Adenocarcinoma of unknown primary: retrospective analysis of chemosensitivity of 313 freshly explanted tumors in a tumor cloning system

Investigational New Drugs

Volumn 13, Issue 1, 1995, Pages 43-49

  Hanauske, Axel R ^a   Clark, Gary M ^b   Von Hoff, Daniel D ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

adenocarcinoma of unknown primary; anticancer drug development; chemosensitivity; in vitro; soft agar colony formation

Indexed keywords

ANTINEOPLASTIC AGENT; BISANTRENE; BLEOMYCIN; CARMUSTINE; CISPLATIN; DACTINOMYCIN; DOXORUBICIN; ECHINOMYCIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; INTOPLICINE; MELPHALAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; TIAZOFURIN; TOPOTECAN; VINBLASTINE; VINZOLIDINE;

ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CHEMOSENSITIVITY; CLONOGENIC ASSAY; DRUG RESISTANCE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGAR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN; NEOPLASMS, UNKNOWN PRIMARY; RETROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; TUMOR STEM CELL ASSAY;

EID: 0029096292     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/BF02614219     Document Type: Article

References (42)

1. Tumors of unknown origin
2. An analysis of 1539 patients with cancer of unknown primary site
3. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site
4. Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site
5. Poorly differentiated neuroendocrine carcinoma of unknown primary tumor site
6. Neoplasms of unknown primary site
7. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience
8. Hainsworth JD, Greco FA: Treatment of patients with cancer of unknown primary site. Important Adv Oncol 173–190, 1991
9. Treatment of patients with cancer of an unknown primary site
10. Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay
11. Primary bioassay of human tumor stem cells
12. The human tumor cloning assay in cancer research and therapy
13. Biphasic effects of vanadium salts on in vitro tumor colony growth
14. Statistical considerations for in vitro/in vivo correlations using a cloning system
15. Human tumor clonogenic assay in patients with unknown primary carcinoma
16. The human tumor clonogenic assay and other cell culture techniques: Potential applications to the study of undifferentiated neoplasms or cancers of unknown origin
17. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site
18. He’s not going to talk about in vitro predictive assays again, is he?
19. Response of primary unknown cancers of treatment with 5-fluorouracil
20. Treatment of the patient with adenocarcinoma of unknown origin
21. Phase II study of oral administration of etoposide for patients with well- and moderately-differentiated adenocarcinoma of unknown primary site
22. 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary
23. Empirical chemotherapy for adenocarcinoma of unknown primary tumor site
24. Empiric chemotherapy in patients with carcinoma of unknown primary site
25. Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results
26. Adenocarcinoma of unknown primary origin: treatment with vindesine and doxurubicin
27. Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary
28. Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens
29. 5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary
30. Combination chemotherapy in the treatment of adenocarcinoma of unknown primary origin
31. A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site
32. Metabolism of hexamethylmelamine-ring-14C in rats and man
33. Preclinical and phase I trials of topoisomerase I inhibitors
34. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities
35. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials
36. Phase I trial and biochemical evaluation of tiazofurin administered on a weekly schedule
37. Phase I and pharmacokinetics study of Tiazofurin (TCAR, NSC 286193) administered by continuous infusion
38. Phase I evaluation and pharmacokinetics of Tiazofurin (2-B-D-ribofuranosylthiazole-4-carboxamide, NSC 286193)
39. Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors
40. Evaluation of creatine analogues as a new class of anticancer agents using freshly explanted human tumor cells
41. Clinical pharmacology of vinzolidine